Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Histone Deacetylase Inhibitor (HDACi)
100%
Insulin-like Growth Factor 2
100%
IGF2
100%
Non-small Cell Lung Cancer (NSCLC)
25%
Inhibitor Resistance
25%
Non-small Cell Lung Cancer Cells
16%
Inhibitor Treatment
16%
Transcription Factor
8%
Cancer Patients
8%
Solid Tumors
8%
Drug Resistance
8%
Hematological Malignancies
8%
MRNA Expression
8%
Signaling Cascades
8%
Proteasomal Degradation
8%
Anticancer Therapy
8%
Clinical Utility
8%
Direct Binding
8%
Pharmacological Strategies
8%
Direct Transcription
8%
Anticancer Therapeutics
8%
Acquired Drug Resistance
8%
Genetic Strategies
8%
Inhibitor Resistant
8%
Patient-derived Tumor Xenograft
8%
IGF1R Signaling
8%
Marginal Resistance
8%
Intrinsic Drug Resistance
8%
Immunology and Microbiology
STAT3
100%
Somatomedin B
100%
Histone
100%
Lung
71%
Drug Resistance
28%
Cancer Cell
28%
Transcription Factors
14%
Promoter Region
14%
Xenograft
14%
Proteasome
14%
Biochemistry, Genetics and Molecular Biology
Histone Deacetylase
100%
STAT3
100%
Insulin-Like Growth Factor 2
100%
Transcription
28%
Cancer Cell
28%
Drug Resistance
28%
Anticancer
28%
Promoter Region
14%
Transcription Factors
14%
Proteasome
14%
Genomics
14%
Messenger RNA
14%
Pharmacology, Toxicology and Pharmaceutical Science
Histone Deacetylase Inhibitor
100%
Somatomedin B
100%
Non Small Cell Lung Cancer
45%
Drug Resistance
18%
Neoplasm
9%
Solid Malignant Neoplasm
9%
Transcription Factors
9%
Hematologic Malignancy
9%
Histone Deacetylase
9%
Proteasome
9%
Messenger RNA
9%